Analysing the cost-effectiveness and future of Australia's Cord Blood Sector

Approach

HealthConsult delivered the project in two phases. Phase 1 involved extensive consultations with 40+ stakeholders across government, the Hematopoietic Stem Cell (HSC) sector, domestic CBBs, clinicians, and international CBBs. We have also obtained and conducted a detailed analysis of the data on 38,000 cord blood units held in the Australian inventory and analysed patient outcomes data held by the Australian Bone Marrow Transplant Recipient Registry. This work was documented in a ‘Phase 1 report’, which set out potential options for the future of the cord blood sector and was submitted in June 2022. Phase 2 delivered a detailed financial and economic analysis to evaluate the cost-effectiveness of the options to determine a recommended future state for the sector.

Outcome

The final report was delivered and accepted by the Department in April 2023. It made 10 recommendations that inform funding and infrastructure investment decisions of governments to position the Australian cord blood sector to provide life-saving treatments more sustainably and efficiently for patients domestically and overseas.

‍

Client

National Blood Authority